Quantum Genomics acquires Eurobiobiz SAS
Quantum Genomics Corp (QGC), a global biotech company developing new drugs for metabolic and cardiovascular diseases, has acquired Eurobiobiz SAS, a company specialising in the identification and development of high value-added projects in the field of life sciences and academic research. Financial terms were not disclosed.
Quantum Genomics Corp (QGC), a global biotech company developing new drugs for metabolic and cardiovascular diseases, has acquired Eurobiobiz SAS, a company specialising in the identification and development of high value-added projects in the field of life sciences and academic research. Financial terms were not disclosed.
QGC's core business is the development of new drugs, mainly through the identification of research projects involving innovative compounds with a high potential of reaching the clinic. Eurobiobiz has developed evaluation method for this type of research project.
The acquisition will mean that a dedicated and experienced team now joins QGC. QGC has already worked with this team for more than a year on the evaluation of a number of scientific projects.
The acquisition will boost QGC's business development and its ability to detect useful molecules, especially in Eastern Europe where Eurobiobiz has good connections and where scientific resources are under-exploited, said Lionel Segard, chairman and ceo of QGC.
Since the company was set up in 1999, Eurobiobiz has trained more than 650 scientists across Europe and has been actively involved in the creation and development phases of more than 40 biotechnology companies, including Newron (Italy), Kibow Biotech (USA) and Aptys Pharmaceuticals (France).